arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

SUTRO BIOPHARMA, INC.

STRO
$9.16 ▼ -0.81 (-8.07%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
38 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
52
Health
Fair
Moderately Bearish
auto_awesome

Analytical Summary

SUTRO BIOPHARMA, INC. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). On the positive side, Return on Common Equity (%) remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $151.8M
Dividend Yield —
Revenue Growth -84.6% ↘
Op. Margin -303.8% ↘
ROIC 28.9% ↘
FCF / Share $-2.31 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

38-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$9.84M
↓ -84.6% —
Net Income Profit after all expenses
$-38.48M
↑ +49.3% —
Operating Margin Operating profit as % of sales
-303.8%
↓ -48.8% 1th
FCF / Share Free cash flow per share
$-2.31
↑ +28.5% —
Long-Term Debt Long-term obligations
$9.78M
↓ -23.4% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓
1
Returns
100
Cash Quality ↑
62

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 11 years · 38 quarters